Biotech Stocks Healthcare Stocks Life Sciences

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Rhythm Biosciences' colorectal cancer test ColoSTAT is officially on the market and has made its first sale. In our view, this could mark the beginning of a major few years…

ByNick Sundich

17

Feb 2026

Biotech Stocks Healthcare Stocks Life Sciences Small Caps Stocks Undervalued Stocks

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The company now has a substantially larger market awaiting us, and…

ByNick Sundich

21

Dec 2023

Uncategorized

Rhythm Biosciences (ASX:RHY): How and why did it all go wrong in 2023 and is there any way back?

Rhythm Biosciences (ASX:RHY) is back to square one after a rollercoaster 3 years. Where did it all go wrong, and is there a way back? All about Rhythm Biosciences…

ByNick Sundich

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Rhythm Biosciences (ASX:RHY): How and why did it all go wrong in 2023 and is there any way back?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Rhythm Biosciences (ASX:RHY): How and why did it all go wrong in 2023 and is there any way back?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here